AKT1 and Hyperglycemia: However, inhibitors of the p-Akt/mTOR pathway such as everolimus, although well tolerated, are reported to be associated with fatigue, hyperglycemia, hypertriglyceridemia, hypercholesterolemia, gastrointestinal syndromes, anorexia, rash, mucositis or headache [25], [26].